Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pharma-Grade CBD for Personal Care - Happi
Company News, Regulations

Pharma-Grade CBD for Personal Care

USDEA removes Purisys' Cannabidiol from Schedule I of Controlled Substances Act. 

Purisys, LLC, a producer of ultra-high purity cannabinoids, announced today that the US Drug Enforcement Agency has removed its cannabidiol (CBD) from Schedule I of the Controlled Substances Act. 
 
Purisys currently produces all major cannabinoids relevant to pharmaceutical and consumer products (>50), as well as degradants, metabolites and analytical reference standards. In addition to CBD, more than 30 other cannabinoids have also been descheduled. 
 
Purisys has been manufacturing ultra-high purity CBD (<0.001% THC) via a patented process since 2016, and its products fall far below the 0.3% THC limits set in the 2018 Farm Bill for use in consumer products. The cannabinoids produced by Purisys are distinguished by their ultra-low THC concentration, purity, world-scale capacity, exacting quality control, ease of formulation compared to hemp-derived isolates, and strong regulatory support, according to the company.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters